Skip to main content
Equibles

Nantahala Capital Management, LLC

Position in TEVA — Teva Pharmaceutical Industries Ltd

CIK 1472322 New Canaan, CT
Back to TEVA Full portfolio

Position in TEVA

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record

Derivatives in TEVA

reported options exposure · as of Mar 31, 2026
CallValue
$45,180,000
CallShares
1,500,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Jun 30, 2026

Nantahala Capital Management, LLC holds $169,874,929 across 9 Drug Manufacturers - Specialty & Generic names.

# Ticker Company Shares Value (USD) Open
1 ETON
Eton Pharmaceuticals, Inc.
 1,175,951 $42,569,426
2 AMRX
Amneal Pharmaceuticals, Inc.
 2,268,751 $39,272,079
3 EOLS
Evolus, Inc.
 5,602,021 $38,878,025
4 BCRX
Biocryst Pharmaceuticals Inc
 1,901,160 $19,011,600
5 ADCT
ADC Therapeutics SA
 12,326,184 $13,189,016
6 AMLX
Amylyx Pharmaceuticals, Inc.
 486,684 $8,740,844
7 TLPH
Talphera, Inc.
 3,492,519 $3,597,294
8 AYTU
Aytu Biopharma, Inc
 1,086,812 $2,336,645

All Filings in TEVA

Export CSV
4 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $45,180,000 1,500,000
2025-12-31 $78,025,000 2,500,000
2025-09-30 $50,500,000 2,500,000
2025-06-30 $16,760,000 1,000,000